Cantor Fitzgerald analyst Chiara Russo says Depomed management in a meeting today noted that trends in opioids with primary care physicians continue to decline while pain specialists appear to be expanding, bringing on nurse practitioners to assist with the patient volumes. Given the company's market share in the pain specialty, this dynamic could be a positive for the Depomed portfolio, Russo tells investors in a research note. This, coupled with the company's restructured sales force, could should benefit by Q2 of this, the analyst contends. Russo keeps a Neutral rating on Depomed with a $23 price target.